Philly De Piante, Director of Marketing at dQ&A, and Mahima Chillakanti, Associate at Close Concerns, recently presented dQ&A data on Advances in Disease-Modifying Interventions at the Global Congress on Cardiology.
This research had four primary objectives:
- Understand the importance of metabolic health in the cardiology and nephrology spaces.
- Discern the potential of SGLT-2s as a disease-modifying therapy for metabolic, kidney, and heart health.
- Evaluate dQ&A’s real-world data on patient experiences with SGLT-2s to better meet patient needs.
- Explore potential areas for further improvement and growth in the use of SGLT-2s for heart, kidney, and metabolic health.
You can view the full presentation below and download the slides.
About dQ&A – The Diabetes Research Company
dQ&A is a social enterprise committed to making life better for people with diabetes. We harness patient voices to drive better business results and better health outcomes. For over 14 years, we have been comprehensively tracking the diabetes experience in the United States, Canada, and Europe. We are trusted by diabetes industry leaders for our independence, commitment, and expertise. Our team has decades of experience in quantitative and qualitative research with a deep knowledge of diabetes. We’re efficient and effective; our insights are actionable and accessible. To learn more, send us an email at email@example.com. For research highlights, visit us at d-qa.com and follow us on LinkedIn (dQ&A – The Diabetes Research Company)